|
PT3590928T
(pt)
|
2011-04-08 |
2021-08-19 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirimidina para o tratamento de infeções virais
|
|
JP6349256B2
(ja)
|
2011-11-09 |
2018-06-27 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染の治療のためのプリン誘導体
|
|
SG11201404743TA
(en)
*
|
2012-02-08 |
2014-09-26 |
Janssen R & D Ireland |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
|
EA035790B1
(ru)
|
2012-07-13 |
2020-08-11 |
Янссен Сайенсиз Айрлэнд Юси |
Макроциклические пурины для лечения вирусных инфекций
|
|
DK2906563T3
(en)
|
2012-10-10 |
2018-06-06 |
Janssen Sciences Ireland Uc |
PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
|
|
EA035431B1
(ru)
|
2012-11-16 |
2020-06-15 |
Янссен Сайенсиз Айрлэнд Юси |
Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
|
|
SG11201506639XA
(en)
|
2013-02-21 |
2015-09-29 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
CN110590809B
(zh)
|
2013-03-29 |
2022-04-19 |
爱尔兰詹森科学公司 |
用于治疗病毒感染的大环脱氮-嘌呤酮
|
|
SG11201509520QA
(en)
|
2013-05-24 |
2015-12-30 |
Janssen Sciences Ireland Uc |
Pyridone derivatives for the treatment of viral infections and further diseases
|
|
PT3030563T
(pt)
|
2013-06-27 |
2017-11-15 |
Janssen Sciences Ireland Uc |
Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
|
|
DK3027624T3
(en)
|
2013-07-30 |
2019-01-07 |
Janssen Sciences Ireland Uc |
THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
|
|
US9670205B2
(en)
|
2015-03-04 |
2017-06-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
US20210292327A1
(en)
|
2015-08-26 |
2021-09-23 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
JP6732915B2
(ja)
|
2015-12-15 |
2020-07-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒト免疫不全ウイルス中和抗体
|
|
EA201892375A1
(ru)
|
2016-05-27 |
2019-08-30 |
Джилид Сайэнс, Инк. |
Способы лечения инфекций, вызываемых вирусом гепатита b
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
MA45539A
(fr)
*
|
2016-07-01 |
2019-05-08 |
Janssen Sciences Ireland Unlimited Co |
Dihydropyranopyrimidines pour le traitement d'infections virales
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
AU2017318601B2
(en)
*
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
CR20190119A
(es)
*
|
2016-09-09 |
2019-06-03 |
Novartis Ag |
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
|
|
ES2912945T3
(es)
|
2016-09-29 |
2022-05-30 |
Janssen Sciences Ireland Unlimited Co |
Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
TW202510891A
(zh)
|
2017-01-31 |
2025-03-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
UY37581A
(es)
|
2017-02-02 |
2018-08-31 |
Gilead Sciences Inc |
Compuestos para el tratamiento de la infección por virus de la hepatitis b
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
CN111051305A
(zh)
|
2017-08-22 |
2020-04-21 |
吉利德科学公司 |
治疗性杂环化合物
|
|
TW201915000A
(zh)
*
|
2017-09-22 |
2019-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
JP7083398B2
(ja)
|
2018-02-15 |
2022-06-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
|
|
EP3752496B1
(en)
|
2018-02-16 |
2023-07-05 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
JP7407740B2
(ja)
|
2018-05-18 |
2024-01-04 |
ノバルティス アーゲー |
Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
|
|
DK4257600T3
(da)
|
2018-07-03 |
2025-05-26 |
Gilead Sciences Inc |
Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
|
|
AU2019297362B2
(en)
|
2018-07-06 |
2022-05-26 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
US11186579B2
(en)
|
2018-07-06 |
2021-11-30 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
KR20210033492A
(ko)
|
2018-07-16 |
2021-03-26 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 캡시드 억제제
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
MX2021002764A
(es)
|
2018-09-12 |
2021-05-12 |
Silverback Therapeutics Inc |
Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
WO2020162705A1
(ko)
|
2019-02-08 |
2020-08-13 |
성균관대학교산학협력단 |
톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
MY201239A
(en)
|
2019-03-22 |
2024-02-13 |
Gilead Sciences Inc |
Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
KR20220035908A
(ko)
|
2019-06-19 |
2022-03-22 |
실버백 테라퓨틱스, 인크. |
항-메소텔린 항체 및 이의 면역접합체
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
KR20240137107A
(ko)
|
2019-07-16 |
2024-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
DK4037708T3
(da)
|
2019-09-30 |
2024-09-30 |
Gilead Sciences Inc |
HBV-vacciner og fremgangsmåder til at behandle HBV
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
ES2973832T3
(es)
|
2019-10-18 |
2024-06-24 |
Forty Seven Inc |
Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CA3157275C
(en)
|
2019-11-26 |
2026-02-10 |
Gilead Sciences, Inc. |
Capsid inhibitors for the prevention of hiv
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
CA3170551A1
(en)
|
2020-03-02 |
2021-09-10 |
Yong Taik Lim |
Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
IL297327B2
(en)
|
2020-05-01 |
2026-01-01 |
Gilead Sciences Inc |
4,2-dioxopyrimidine compounds CD73 inhibitors
|
|
JP7741100B2
(ja)
|
2020-05-04 |
2025-09-17 |
アムジェン インコーポレイテッド |
ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
|
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
TWI858267B
(zh)
|
2020-06-25 |
2024-10-11 |
美商基利科學股份有限公司 |
用於治療hiv之蛋白殼抑制劑
|
|
JP2023532304A
(ja)
|
2020-07-01 |
2023-07-27 |
エーアールエス ファーマシューティカルズ オペレーションズ，インク． |
抗ａｓｇｒ１抗体コンジュゲートおよびその使用
|
|
US20230277525A1
(en)
|
2020-08-04 |
2023-09-07 |
Progeneer Inc |
Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
|
|
JP7690221B2
(ja)
|
2020-08-04 |
2025-06-10 |
プロジェニア インコーポレイテッド |
動力学的に作用するアジュバントアンサンブル
|
|
US20230346924A1
(en)
|
2020-08-04 |
2023-11-02 |
Progeneer Inc. |
Mrna vaccine comprising adjuvant capable of kinetic control
|
|
EP4192474B1
(en)
|
2020-08-07 |
2025-09-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
PL4244396T3
(pl)
|
2020-11-11 |
2025-12-22 |
Gilead Sciences, Inc. |
Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
US12084467B2
(en)
|
2021-12-03 |
2024-09-10 |
Gilead Sciences, Inc. |
Therapeutic compounds for HIV virus infection
|
|
CR20240223A
(es)
|
2021-12-03 |
2024-07-08 |
Gilead Sciences Inc |
Compuestos terapéuticos para la infección por el virus del vih
|
|
US12404262B2
(en)
|
2021-12-03 |
2025-09-02 |
Gilead Sciences, Inc. |
Therapeutic compounds for HIV virus infection
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20250059183A1
(en)
*
|
2021-12-08 |
2025-02-20 |
Shanghai Visonpharma Co., Ltd. |
Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TW202446773A
(zh)
|
2022-04-06 |
2024-12-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
TWI867601B
(zh)
|
2022-07-01 |
2024-12-21 |
美商基利科學股份有限公司 |
可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
AU2023330037A1
(en)
|
2022-08-26 |
2025-03-06 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20240226130A1
(en)
|
2022-10-04 |
2024-07-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20240390349A1
(en)
|
2023-04-19 |
2024-11-28 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
CN121219281A
(zh)
|
2023-05-31 |
2025-12-26 |
吉利德科学公司 |
用于治疗hiv的化合物的固体形式
|
|
US20250042926A1
(en)
|
2023-05-31 |
2025-02-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
US20250127801A1
(en)
|
2023-10-11 |
2025-04-24 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250122219A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250230163A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20250296932A1
(en)
|
2024-03-01 |
2025-09-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20250333424A1
(en)
|
2024-03-01 |
2025-10-30 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
WO2025184452A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260007683A1
(en)
|
2024-06-14 |
2026-01-08 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026076265A1
(en)
|
2024-10-03 |
2026-04-09 |
Gilead Sciences, Inc. |
Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors
|